Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rulonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for advanced, persistent, recurrent, or metastatic cervical cancer
CTR20242664Phase 3Active
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rulonilimab in Cervical Cancer (CC), sponsored by Shandong New Era Pharmaceutical. Started Sep 2024; status: active.
02
Drugs
rulonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20242664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242664.